CALGARY, Jan. 5, 2017 /CNW/ - Zenith Capital Corp. ("Zenith" or the "Company") today announces its participation in the upcoming 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.
Date: January 9th
Time: 9:45 am PT
Duration: 15 minutes
Location: Room 9 (Ballroom Level) at the Hilton San Francisco Union Square
Mr. McCaffrey's presentation will be available on the Company website on the Presentations & Publications page immediately prior to the scheduled presentation time.
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.'s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer ("mCRPC").
SOURCE Zenith Capital Corp.
For further information: Clayton Paradis, Zenith Capital Corp., Phone: 587-390-7865, Email: firstname.lastname@example.org